Search

Your search keyword '"Statland, Jeffrey"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Statland, Jeffrey" Remove constraint Author: "Statland, Jeffrey" Search Limiters Full Text Remove constraint Search Limiters: Full Text
172 results on '"Statland, Jeffrey"'

Search Results

1. Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study.

2. Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

3. Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

4. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.

5. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

6. Patient reported quality of life in limb girdle muscular dystrophy

7. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

8. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.

10. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial

11. Review of the Diagnosis and Treatment of Periodic Paralysis

13. Autosomal dominant in cis D4Z4 repeat array duplication alleles in facioscapulohumeral dystrophy

14. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

15. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

16. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

18. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

20. The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure

21. Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis

22. Autosomal dominant in cis D4Z4 repeat array duplication alleles in facioscapulohumeral dystrophy

24. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis—insights from a completed randomized controlled trial with rasagiline.

25. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

26. Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): a national, cross-sectional study

27. Consensus-based care recommendations for adults with myotonic dystrophy type 1

29. Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI Composite Scores for Longitudinal and Cross-sectional Analysis

30. Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability

31. The Changing Health and Social Circumstances of Women Leaving Jails: A Three-Year Longitudinal Study

32. Demographics, Clinical Characteristics, and Prognostic Factors of ALS in Midwest

33. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

35. Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

36. Additional file 4 of Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy

37. Additional file 2 of A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

38. Additional file 3 of A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

39. Additional file 4 of A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

41. Additional file 1 of Phenotypic diversity in an international Cure VCP Disease registry

42. Additional file 2 of Phenotypic diversity in an international Cure VCP Disease registry

48. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

49. Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study

Catalog

Books, media, physical & digital resources